Evidence map›Paper›PMID 37204528›Full record

ArticleEJNMMI research2023

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression.

Ulrika Jahn, Ulrike Garske-Román, Mattias Sandström, Mark Lubberink, Anders Sundin

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ulrika JahnDepartment of Surgical Sciences, Nuclear Medicine and PET, Uppsala University Hospital, 751 85, Uppsala, Sweden. ulrika.jahn@radiol.uu.se.ORCID http://orcid.org/0000-0001-8038-2413
Ulrike Garske-RománDepartment of Blood and Tumor Diseases, Uppsala University Hospital, Uppsala, Sweden.
Mattias SandströmDepartment of Surgical Sciences, Nuclear Medicine and PET, Uppsala University Hospital, 751 85, Uppsala, Sweden.
Mark LubberinkDepartment of Surgical Sciences, Nuclear Medicine and PET, Uppsala University Hospital, 751 85, Uppsala, Sweden.
Anders SundinDepartment of Surgical Sciences, Nuclear Medicine and PET, Uppsala University Hospital, 751 85, Uppsala, Sweden.
Uppsala University Hospital · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe accumulation of

methodPatients with small intestinal (n = 141) and pancreatic (n = 62) neuroendocrine tumors (NETs) who underwent PRRT were selected for retrospective evaluation. All patients had received 7.4 GBq

resultsThere was no correlation between the amount of peptide and any of the tested parameters in relation to tTSSTRE.

conclusionIn this retrospective analysis, no correlation between the amount of administered peptide in the

Indexed as

Pancreatic NETPeptidePRRTSmall intestinal NETSomatostatin receptorSUV

Identifiers

PMID37204528
PMCPMC10199148
OpenAlexW4377093506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.